Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up

Xiaohan Liu1–3,* Biao Song1–3,* Hongzhong Jin1–3

1Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China; 2State Key Laboratory of Complex Severe and Rare Diseases, Beijing, People’s Republic of China; 3National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Hongzhong Jin, Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, 100730, People’s Republic of China, Email jinhongzhong@263.net

Abstract: Atopic dermatitis (AD) may sometimes be comorbid with alopecia areata (AA). However, traditional treatments for AA show limited efficacy. New treatment options, such as dupilumab and Janus kinase inhibitors, have proven efficacy in addressing both AD and AA. This article highlights the challenging case of a 12-year-old boy experiencing severe refractory AD and comorbid AA treated with oral abrocitinib after dupilumab failure with 1-year follow-up. After 3 months of treatment, his skin manifestations improved and the hair completely regenerated. No adverse reactions were observed during the 1-year follow-up period. This case provides evidence of the efficacy and safety of using abrocitinib to treat pediatric patients with both AD and AA.

Keywords: atopic dermatitis, alopecia areata, Janus kinase inhibitors, dupilumab

Introduction

Atopic dermatitis (AD) is a common chronic inflammatory skin disease in childhood. Children with AD often have a personal or family history of atopic diseases such as food allergies, allergic rhinitis, and asthma. AD affects approximately 15% to 20% of children, 5% to 20% of adolescents, and 1% to 3% of adults.1 It is characterized by recurrent eczematous skin lesions accompanied by intense itching, significantly impacting patients’ quality of life.2 Additionally, moderate to severe AD is associated with increased rates of anxiety, depression, and sleep disturbances, affecting patients’ mental health and contributing to a considerable public health burden.3,4

Alopecia areata (AA) is a condition characterized by hair loss without scarring and affects approximately 2% of people worldwide.5 Because of its aesthetic impact, patients with AA often experience psychological distress. AD can also sometimes be comorbid with AA, and a bilateral association between AD and AA has been reported.6–8 AD is considered a classic Th2 inflammatory disease, whereas the precise pathophysiology of AA remains unclear. Both Th1 and Th2 inflammation may contribute to the development of AA.9 Their pathogenesis involves various cytokines, such as interleukins (ILs) and interferons, which mediate inflammatory signaling through the Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway.10

Several biologics and JAK inhibitors are available for moderate to severe AD in adolescents, including dupilumab (IL-4/IL-13 inhibitor), tralokinumab (IL-13 inhibitor), lebrikizumab (IL-13 inhibitor), nemolizumab (IL-31 inhibitor), abrocitinib (JAK1 inhibitor), and upadacitinib (JAK1 inhibitor).11–16 However, conventional treatments for AA in
adolescents show limited efficacy, and there is still insufficient evidence regarding the safety and efficacy of biologics and JAK inhibitors.\textsuperscript{17}

We herein share our experience of treating a 12-year-old boy with abrocitinib. This therapeutic strategy was utilized to manage severe and unresponsive AD and AA following an unsuccessful attempt with dupilumab.

**Case Presentation**

The patient was a 12-year-old boy who weighed 101 kg and had a history of AD since childhood. He presented with recurrent erythema, scales, and severe itching [Pruritus-Numeric Rating Scale (P-NRS) score of 8/10] on his face, trunk, and extremities 18 months previously and a round patch of hair loss on the scalp 16 months prior. Previous treatment with oral Chinese herbal medicine, oral antihistamines, and dupilumab for 4 months (initial dose of 600 mg, followed by 300 mg every 2 weeks) resulted in minimal improvement. Physical examination showed extensive symmetrical red patches and papules with scales on his face, trunk, and extremities, notably accompanied by significant yellow crusts and exudates on his face [Investigator’s Global Assessment (IGA) score of 5, Eczema Area Severity Index (EASI) score of 34] (Figure 1a, c–e). The occipital scalp showed a coin-sized patch of hair loss (Figure 1b). Routine laboratory tests showed an increased immunoglobulin E level (510 kU/L). Other laboratory values, including complete blood counts, liver and kidney function tests, tumor markers, hepatitis markers, and screening tests for tuberculosis, were normal. The patient was diagnosed with severe AD and treated with oral abrocitinib (200 mg/day). After 12 weeks of treatment, his skin manifestations improved significantly, and hair regrowth occurred in the affected area of the scalp [P-NRS score of 2/10, IGA score of 1, EASI score of 2.2] (Figure 2a–e). The dose of abrocitinib was then reduced to 100 mg once daily, and the patient remained under treatment and follow-up. More than 1 year after commencement of therapy, the patient had experienced complete resolution of his AA symptoms with only mild relapse of the AD lesions [IGA score of ≤2] during the follow-up period, and no adverse events had been observed.

![Figure 1](https://doi.org/10.2147/JAA.S458684)

**Figure 1** Clinical photographs at baseline. Extensive symmetrical red patches and papules with crusts and scales were observed on the patient's (a) face, (c) trunk, and (d and e) extremities. (b) The occipital scalp showed a coin-sized patch of hair loss.
Discussion

This case provides information on the use of abrocitinib in a pediatric patient with both AD and AA after dupilumab failure with 1-year follow-up.

Systemic treatments for severe AD with AA may involve glucocorticoids, immunosuppressants, dupilumab, and JAK inhibitors. Because of long-term safety concerns in pediatric patients, we avoided glucocorticoids and immunosuppressants in the present case. Dupilumab is expected to have a therapeutic effect on AD and AA by down-regulating Th2 inflammation through the blockade of IL-4/13 signaling. However, drug resistance and potential AA exacerbation have been reported. JAK inhibitors affect both Th1-dominant and Th2-dominant states by targeting interferon-γ/IL-15 in addition to IL-4/13. Only ritlecitinib (JAK3 inhibitor) has been approved for the treatment of AA in patients aged ≥12 years, but indications for its use in the treatment of AD are lacking. Most reports on the use of other JAK inhibitors in pediatric patients with AA are case reports, and the long-term safety remains unclear. Kołcz et al conducted a comprehensive literature review on the use of JAK inhibitors for treating pediatric AA, including tofacitinib (JAK1/3 inhibitor, with minimal JAK2 inhibition), baricitinib (JAK1/2 inhibitor), and ruxolitinib (JAK1/2 inhibitor). Side effects include mild headaches, upper respiratory tract infections, mild elevation of liver enzymes, diarrhea, and others. Based on this review, we have summarized the latest reports of JAK inhibitor treatment for pediatric AA in the past 2 years (Table 1). Six cases involved the use of upadacitinib (selective JAK1 inhibitor) and abrocitinib (selective JAK1 inhibitor) in treating pediatric patients with AA, showing good tolerability. Upadacitinib and abrocitinib have been approved for severe AD in children aged ≥12 years. Selective JAK1 inhibitors have potential safety advantages because of their specific pathway targeting, offering greater JAK2-related hematopoietic function preservation than non-selective inhibitors.

We also conducted an in-depth review of cases in which selective JAK1 inhibitors were used in pediatric patients with comorbid AD and AA. To our knowledge, there has been no prior report of successful treatment of comorbid AD and AA by switching to abrocitinib after dupilumab failure (Table 2). Throughout our 1-year follow-up, we observed a favorable response to abrocitinib with no adverse reactions, suggesting its safety in treating such conditions in children.

This case report had two main limitations. First, the patient had relatively mild AA. Although abrocitinib might be effective in patients with severe AD and severe AA, further confirmation is still required. Second, whether the outcome
Table 1 Summary of Cases of AA in Pediatric Patients Treated with Systemic JAK Inhibitors in the Most Recent 2 Years

<table>
<thead>
<tr>
<th>Report</th>
<th>Study Type</th>
<th>JAK Inhibitor</th>
<th>Dose</th>
<th>N</th>
<th>Age, y</th>
<th>Outcome</th>
<th>Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ma Y (2024)</td>
<td>Case report</td>
<td>Tofacitinib</td>
<td>5 mg QD</td>
<td>1</td>
<td>6</td>
<td>Complete hair regrowth</td>
<td>None</td>
</tr>
<tr>
<td>Zhou J et al (2023)</td>
<td>Retrospective cohort study</td>
<td>Tofacitinib</td>
<td>5 mg QD</td>
<td>5</td>
<td>3–14</td>
<td>Partial or complete hair regrowth (100%)</td>
<td>Excessive hair growth (n = 1)</td>
</tr>
<tr>
<td>Yousef S et al (2023)</td>
<td>Case series</td>
<td>Tofacitinib</td>
<td>5 mg QD (n = 1), tapered up from 5 to 10 mg BID (n = 4), 10 mg BID (n = 5)</td>
<td>10</td>
<td>7–16</td>
<td>Complete hair regrowth (100%)</td>
<td>Mild facial acne (n = 1)</td>
</tr>
<tr>
<td>Huang J et al (2023)</td>
<td>Case series</td>
<td>Tofacitinib</td>
<td>5 mg QD (n = 4), tapered up from 5 mg QD to BID (n = 2), 5 mg BID (n = 5)</td>
<td>11</td>
<td>7–12</td>
<td>Partial or complete hair regrowth (73%)</td>
<td>Mild increases in liver transaminase levels (n = 1), low haemoglobin (n = 1), folliculitis and elevated uric acid (n = 1)</td>
</tr>
<tr>
<td>Wagh N (2023)</td>
<td>Case report</td>
<td>Tofacitinib</td>
<td>5 mg BID</td>
<td>1</td>
<td>14</td>
<td>Complete hair regrowth</td>
<td>None</td>
</tr>
<tr>
<td>Geng SL et al (2022)</td>
<td>Case series</td>
<td>Tofacitinib</td>
<td>2.5 mg BID (n = 4), 2.5 mg + 5 mg (n = 1)</td>
<td>5</td>
<td>3–5</td>
<td>Significant or complete hair regrowth (100%)</td>
<td>Mild elevation of liver transaminase levels (n = 2)</td>
</tr>
<tr>
<td>Bhokare A (2022)</td>
<td>Case report</td>
<td>Tofacitinib</td>
<td>Tapered up from 2.5 mg QD to BID</td>
<td>1</td>
<td>8</td>
<td>Complete hair regrowth</td>
<td>None</td>
</tr>
<tr>
<td>Moussa A et al (2023)</td>
<td>Retrospective review</td>
<td>Baricitinib</td>
<td>Mean final dose 3.9 mg/d</td>
<td>29</td>
<td>12–17</td>
<td>Partial or complete hair regrowth (79%)</td>
<td>Mild: conjunctivitis (n = 1), neutropenia (n = 3), hypercholesterolaemia (n = 5), hypertriglyceridaemia (n = 2), transaminits (n = 3), and elevated serum creatinine (n = 4)</td>
</tr>
<tr>
<td>Zhan J et al (2023)</td>
<td>Case series</td>
<td>Baricitinib</td>
<td>2 mg QD (n =3), 2 mg BID (n =2)</td>
<td>5</td>
<td>7–18</td>
<td>Significant hair regrowth (80%)</td>
<td>Mild infection (n = 1)</td>
</tr>
<tr>
<td>Asfour L et al (2023)</td>
<td>Retrospective cohort study</td>
<td>Baricitinib</td>
<td>Mean dose 4 mg/d</td>
<td>19</td>
<td>8–12</td>
<td>Significant or complete hair regrowth (79%)</td>
<td>Mild acne (n= 2), self-limiting cold sore (n = 1), high cholesterol (n = 4), hypertriglyceridaemia (n = 1), mild neutropenia (n = 3)</td>
</tr>
<tr>
<td>Rotaru S et al (2023)</td>
<td>Case report</td>
<td>Baricitinib</td>
<td>2 mg/d</td>
<td>1</td>
<td>8</td>
<td>Treatment was stopped due to severe tinea capitis</td>
<td>Severe tinea capitis</td>
</tr>
<tr>
<td>Kolcz K et al (2018)</td>
<td>Case report</td>
<td>Upadacitinib</td>
<td>15 mg QD</td>
<td>1</td>
<td>14</td>
<td>Complete hair regrowth</td>
<td>Transient leukopenia</td>
</tr>
<tr>
<td>Yu D et al (2023)</td>
<td>Case report</td>
<td>Upadacitinib</td>
<td>15 mg QD</td>
<td>1</td>
<td>9</td>
<td>Complete hair regrowth</td>
<td>None</td>
</tr>
<tr>
<td>Ha GU et al (2023)</td>
<td>Case report</td>
<td>Upadacitinib</td>
<td>15 mg QD</td>
<td>1</td>
<td>15</td>
<td>Significant hair regrowth</td>
<td>None</td>
</tr>
<tr>
<td>Bourkas AN et al (2022)</td>
<td>Case report</td>
<td>Upadacitinib</td>
<td>NA</td>
<td>1</td>
<td>14</td>
<td>Significant hair regrowth</td>
<td>NA</td>
</tr>
<tr>
<td>Zhao J et al (2024)</td>
<td>Case report</td>
<td>Abrocitinib</td>
<td>200 mg QD</td>
<td>1</td>
<td>14</td>
<td>Complete hair regrowth</td>
<td>None</td>
</tr>
<tr>
<td>Huang J et al (2024)</td>
<td>Case report</td>
<td>Abrocitinib</td>
<td>100 mg QD</td>
<td>1</td>
<td>11</td>
<td>Significant hair regrowth</td>
<td>None</td>
</tr>
<tr>
<td>Current case</td>
<td>Case report</td>
<td>Abrocitinib</td>
<td>200 mg QD</td>
<td>1</td>
<td>12</td>
<td>Complete hair regrowth</td>
<td>None</td>
</tr>
</tbody>
</table>

Abbreviations: M, male; F, female; AA, alopecia areata; N, number of pediatric patients; QD, once a day; BID, twice a day; NA, not available.
in our case was due to a delayed response to dupilumab treatment or spontaneous remission of AA remains unknown. Additional reports are needed to confirm the efficacy of abrocitinib for AA.

Conclusion
Our report demonstrates that abrocitinib may offer an effective and safe treatment option for pediatric patients with both AA and AD, especially when dupilumab results in an inadequate response. Further research is needed to confirm its efficacy in treating AA.

Informed Consent
Written informed consent was obtained from the patient’s mother to publish the details of this case, including publication of the images.

Acknowledgments
We thank the patient’s mother for granting permission to publish this information.

Funding
This work was supported by the National High-Level Hospital Clinical Research Funding [2022-PUMCH-B-092] and the National Key Clinical Specialty Project of China.

Disclosure
The authors report no conflicts of interest in this work.

References

---

**Table 2 Summary of Comorbid Cases of AD and AA in Pediatric Patients Treated with Selective JAK1 Inhibitors**

<table>
<thead>
<tr>
<th>Report</th>
<th>Age, y</th>
<th>Sex</th>
<th>Duration of AA (Months)</th>
<th>Previous Treatments</th>
<th>Reasons for changing Treatment</th>
<th>JAK Inhibitor</th>
<th>Duration of Treatment</th>
<th>Outcome</th>
<th>Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bourkas AN et al (2022)</td>
<td>14</td>
<td>M</td>
<td>156</td>
<td>Intraleisional corticosteroid injections, TCS, topical tacrolimus, oral cyclosporine, methotrexate, systemic minoxidil</td>
<td>New-onset hair loss with a dermatitis flare-up</td>
<td>Upadacitinib</td>
<td>5 months</td>
<td>Remission of AA and AD</td>
<td>NA</td>
</tr>
<tr>
<td>Kołcz K et al (2023)</td>
<td>14</td>
<td>F</td>
<td>12</td>
<td>Topical minoxidil, TCS, topical diphencyprone, NB- UVB</td>
<td>No response</td>
<td>Upadacitinib</td>
<td>3 months</td>
<td>Remission of AA and AD</td>
<td>Transient leukopenia</td>
</tr>
<tr>
<td>Yu D et al (2023)</td>
<td>9</td>
<td>F</td>
<td>84</td>
<td>TCS, topical minoxidil, tacrolimus and oral compound glycyrrhizin tablets, and glucocorticoids</td>
<td>No response</td>
<td>Upadacitinib</td>
<td>5 months</td>
<td>Remission of AA and AD</td>
<td>None</td>
</tr>
<tr>
<td>Zhao J et al (2022)</td>
<td>14</td>
<td>F</td>
<td>36</td>
<td>TCS, oral antihistamines, Chinese acupuncture treatments</td>
<td>No response</td>
<td>Abrocitinib</td>
<td>Over 2 years</td>
<td>Remission of AA and AD</td>
<td>None</td>
</tr>
<tr>
<td>Current case</td>
<td>12</td>
<td>M</td>
<td>16</td>
<td>Oral Chinese herbal medicine, oral antihistamines, dupilumab</td>
<td>No response</td>
<td>Abrocitinib</td>
<td>Over 1 year (ongoing)</td>
<td>Remission of AA and AD</td>
<td>None</td>
</tr>
</tbody>
</table>

Abbreviations: M, male; F, female; AD, atopic dermatitis; AA, alopecia areata; TCS, topical glucocorticoids; NB-UVB, narrow-band ultraviolet B.


